UAB Leads Test of New HIV Drug
BIRMINGHAM, Ala. -- A study underway at the University of Alabama at Birmingham (UAB) aims to determine whether the first of a new class of HIV drugs is safe and effective in preventing the virus from entering healthy cells.
The national multi-center study is led by Michael Saag, MD, professor of medicine and director of UAB's Center for AIDS Research.
"Despite impressive advances in the treatment of HIV/AIDS, there is a need for new drugs to treat patients who have developed drug resistance to current therapies. This new drug, called AMD11070, is one of the more promising ones to make it into clinical trials, Saag said.
More information, including a list of participating sites, is available at http://www.clinicaltrials.gov.
Source: UAB
Chief Infection Prevention Officer: Leading the Way Into the Future
December 7th 2023The role and responsibility of executive-level oversight in infection prevention is growing. Expertise, determination, consistency, and sustainability bring value to reducing healthcare–associated infections, preventing harm, and supporting a safe workplace.
